Skip to main content
Caplight Logo









Doutor123

Doutor123

Private
São PauloHealthcare & Life Scienceshttps://www.doutor123.com.br/

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Doutor123 operates in Healthcare & Life Sciences and is based in São Paulo. It was founded in 2016.

Doutor123 is a healthtech company that provides an online platform for scheduling medical consultations, exams, and accessing integrated health benefits for employees and individuals.

Sector

Healthcare & Life Sciences

Verticals

Telemedicine, Patient Engagement, Medical AI, HR

Business Model

B2B2C

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Doutor123 Comparables

Compare Doutor123 with similar companies based on industry and business-model similarity.

Doutor123 comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VidaClass
86%
Fácil Consulta
84%
Conexa Saúde
74%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Doutor123 Funding Rounds

Historical fundraising activity

Funding history

No completed funding rounds are published for Doutor123. Book a demo to ask about coverage.

Book a demo

For institutional investors. Book with your work email.

Key People

Founding team and executive leadership

Sandra Dias

Chief Executive Officer (CEO)

Executive Team

For institutional investors. Book with your work email.

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 70% MoM, reaching 1.3K.

  • Jun 19, 2026

    Monthly visitors grew 36% MoM, from 518 to 704.

Book a demo to see all signals

For institutional investors. Book with your work email.

Doutor123 Filings

Explore SEC and related filing metadata, where available.

Doutor123 filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Doutor123's valuation, stock price, and market status.

Is Doutor123 a public or private company?

Doutor123 is a private company.

What is the current stock price of Doutor123?

Doutor123 is a private company, so its shares have no public market price. Caplight tracks Doutor123's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Doutor123 worth (valuation)?

Valuation information for Doutor123 is not publicly available.

Can I buy Doutor123 stock?

Doutor123 shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Doutor123's last funding round?

Funding round information for Doutor123 is not publicly available.

Who are the main investors in Doutor123?

Investor information for Doutor123 is not publicly disclosed.

Will Doutor123 IPO soon?

No public IPO plans have been announced for Doutor123.

How can I track Doutor123 secondary market activity?

Caplight tracks bids, offers, and trades in Doutor123's shares on secondary markets.

Firmographic Details

HeadquartersSão Paulo
Employee Range7
Year Founded2016
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?